Somatostatin administration prior to ERCP is effective in reducing the risk of post-ERCP pancreatitis in high-risk patients

Zhao,Li-Na; Yu,Tao; Li,Chu-Qiang; Lai,Yu; Chen,Qi-Kui

doi:10.3892/etm.2014.1733

Somatostatin administration prior to ERCP is effective in reducing the risk of post-ERCP pancreatitis in high-risk patients

Authors:
- Li-Na Zhao
- Tao Yu
- Chu-Qiang Li
- Yu Lai
- Qi-Kui Chen
View Affiliations

Affiliations: Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China
Published online on: May 26, 2014 https://doi.org/10.3892/etm.2014.1733
Pages: 509-514

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Somatostatin has been extensively studied for the prophylaxis of pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP). However, the results remain controversial. The present retrospective cohort study aimed to investigate the efficacy of pre- and post-ERCP somatostatin administration in the prevention of post-ERCP pancreatitis (PEP). All ERCP procedures performed at one hospital between January 2009 and December 2012 were reviewed. They were divided into three groups based on somatostatin administration: pre-ERCP som group (somatostatin administration: 0.25 mg/h for 24 h, starting 1 h prior to ERCP), post-ERCP som group (somatostatin administration: 0.25 mg/h for 24 h, starting immediately following ERCP), and control group (no somatostatin administration). Out of a total of 304 cases, 81 received pre-ERCP somatostatin; 126 received post-ERCP somatostatin and 97 were not administered somatostatin. Pre-ERCP somatostatin was effective in reducing the incidence of PEP compared with that in the control group (4.9 vs. 16.5%; P=0.017). This benefit was significant in high-risk patients (8.9 vs. 26.0%; P=0.035), but not in low-risk patients (0 vs. 6.4%; P=0.254). Post-ERCP somatostatin was not effective in preventing PEP in high- or low-risk patients. In conclusion, pre-ERCP somatostatin may be effective in reducing the risk of PEP in high-risk patients, but not in low-risk patients. Post?ERCP somatostatin did not reveal a benefit in high- or low-risk patients. However, large randomized controlled trials are required to further confirm these ?ndings.

View Figures

View References

1	Cohen S, Bacon BR, Berlin JA, et al: National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14–16. Gastrointest Endosc. 56:803–809. 2002.PubMed/NCBI
2	Masci E, Mariani A, Curioni S and Testoni PA: Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy. 35:830–834. 2003. View Article : Google Scholar : PubMed/NCBI
3	Donnellan F and Byrne MF: Prevention of post-ERCP pancreatitis. Gastroenterol Res Pract. 2012:7967512012. View Article : Google Scholar : PubMed/NCBI
4	Dumonceau JM, Andriulli A, Deviere J, Mariani A, Rigaux J, Baron TH and Testoni PA; European Society of Gastrointestinal Endoscopy. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy. 42:503–515. 2010. View Article : Google Scholar : PubMed/NCBI
5	Lee KT, Lee DH and Yoo BM: The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial. Pancreas. 37:445–448. 2008. View Article : Google Scholar
6	Andriulli A, Clemente R, Solmi L, et al: Gabexate or somatostatin administration before ERCP in patients at high-risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc. 56:488–495. 2002. View Article : Google Scholar
7	Andriulli A, Solmi L, Loperfido S, et al: Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol. 2:713–718. 2004.PubMed/NCBI
8	Arvanitidis D, Anagnostopoulos GK, Giannopoulos D, et al: Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol. 19:278–282. 2004. View Article : Google Scholar : PubMed/NCBI
9	Bordas JM, Toledo-Pimentel V, Llach J, Elena M, Mondelo F, Ginès A and Terés J: Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc. 47:230–234. 1998. View Article : Google Scholar : PubMed/NCBI
10	Persson B, Slezak P, Efendic S and Häggmark A: Can somatostatin prevent injection pancreatitis after ERCP? Hepatogastroenterology. 39:259–261. 1992.PubMed/NCBI
11	Poon RT, Yeung C, Liu CL, et al: Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomized controlled trial. Gut. 52:1768–1773. 2003. View Article : Google Scholar
12	Poon RT, Yeung C, Lo CM, Yuen WK, Liu CL and Fan ST: Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc. 49:593–598. 1999. View Article : Google Scholar : PubMed/NCBI
13	Guelrud M, Mendoza S, Viera L and Gelrud D: Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc. 37:44–47. 1991. View Article : Google Scholar
14	Cotton PB, Lehman G, Vennes J, et al: Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 37:383–393. 1991. View Article : Google Scholar : PubMed/NCBI
15	Cooper ST and Slivka A: Incidence, risk factors, and prevention of post-ERCP pancreatitis. Gastroenterol Clin North Am. 36:259–276. 2007. View Article : Google Scholar : PubMed/NCBI
16	Gullo L, Priori P, Scarpignato C, Baldoni F, Mattioli G and Barbara L: Effect of somatostatin 14 on pure human pancreatic secretion. Dig Dis Sci. 32:1065–1070. 1987. View Article : Google Scholar : PubMed/NCBI
17	Karalis K, Mastorakos G, Chrousos GP and Tolis G: Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest. 93:2000–2006. 1994. View Article : Google Scholar : PubMed/NCBI
18	Lai KH, Lo GH, Cheng JS, et al: Effect of somatostatin on the sphincter of Oddi in patients with acute non-biliary pancreatitis. Gut. 49:843–846. 2001. View Article : Google Scholar : PubMed/NCBI
19	Omata F, Deshpande G, Tokuda Y, et al: Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis. J Gastroenterol. 45:885–895. 2010. View Article : Google Scholar : PubMed/NCBI
20	Wang Z, Li W and Wu L: Could somatostatin prevent post-ERCP pancreatitis or hyperamylasemia? A randomized, double blind, controlled preliminary clinical trial. Gastrointest Endosc. 71:AB2992010. View Article : Google Scholar
21	Testoni PA, Giussani A, Vailati C, Testoni S, Di Leo M and Mariani A: Precut sphincterotomy, repeated cannulation and post-ERCP pancreatitis in patients with bile duct stone disease. Dig Liver Dis. 43:792–796. 2011. View Article : Google Scholar : PubMed/NCBI